Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nichimo Biotics is a Japanese biotechnology company specializing in the development and manufacture of functional food ingredients and dietary supplements derived from fermented natural sources. A subsidiary of Nichimo Co., Ltd., the company leverages proprietary fermentation technologies, particularly using Aspergillus oryzae (Koji), to produce bioactive compounds like AglyMax and ImunoBran. AglyMax is a soy isoflavone aglycone designed for superior absorption, primarily targeting women's health and bone density. ImunoBran, also known as MGN-3, is a modified rice bran arabinoxylan used globally for immune system modulation and as a complementary therapy in oncology. The company maintains a strong focus on evidence-based research, collaborating with universities to validate the efficacy and safety of its products. Nichimo Biotics serves the global market, providing high-quality ingredients to the pharmaceutical, nutraceutical, and functional food industries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nichimo Biotics.